Callan Family Office LLC bought a new stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 4,116 shares of the medical instruments supplier's stock, valued at approximately $1,478,000.
A number of other hedge funds have also modified their holdings of WST. Bank of Nova Scotia boosted its stake in West Pharmaceutical Services by 337.8% during the first quarter. Bank of Nova Scotia now owns 65,323 shares of the medical instruments supplier's stock valued at $16,373,000 after buying an additional 50,402 shares during the last quarter. Hsbc Holdings PLC lifted its stake in shares of West Pharmaceutical Services by 23.3% during the 4th quarter. Hsbc Holdings PLC now owns 146,872 shares of the medical instruments supplier's stock worth $40,425,000 after acquiring an additional 27,745 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in West Pharmaceutical Services by 100.2% during the 1st quarter. Renaissance Technologies LLC now owns 209,660 shares of the medical instruments supplier's stock valued at $52,549,000 after acquiring an additional 104,924 shares during the period. Conestoga Capital Advisors LLC grew its position in West Pharmaceutical Services by 6.7% in the 1st quarter. Conestoga Capital Advisors LLC now owns 130,970 shares of the medical instruments supplier's stock valued at $32,826,000 after acquiring an additional 8,179 shares during the last quarter. Finally, Comerica Bank grew its position in West Pharmaceutical Services by 31.8% in the 4th quarter. Comerica Bank now owns 56,693 shares of the medical instruments supplier's stock valued at $15,599,000 after acquiring an additional 13,680 shares during the last quarter. 93.90% of the stock is currently owned by institutional investors.
West Pharmaceutical Services Price Performance
WST opened at $352.94 on Monday. West Pharmaceutical Services, Inc. has a 12-month low of $223.83 and a 12-month high of $386.00. The company has a current ratio of 2.82, a quick ratio of 2.12 and a debt-to-equity ratio of 0.07. The business's fifty day simple moving average is $348.61 and its 200-day simple moving average is $300.19. The company has a market capitalization of $24.84 billion, a price-to-earnings ratio of 45.19, a PEG ratio of 2.47 and a beta of 1.15.
West Pharmaceutical Services (NYSE:WST - Get Free Report) last released its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share for the quarter, beating the consensus estimate of $2.08 by $0.29. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The firm had revenue of $872.30 million during the quarter, compared to the consensus estimate of $839.98 million. During the same period in the previous year, the company posted $1.84 earnings per share. The firm's quarterly revenue was up 13.8% on a year-over-year basis. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. On average, equities research analysts anticipate that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current fiscal year.
West Pharmaceutical Services Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th were given a dividend of $0.22 per share. The ex-dividend date of this dividend was Wednesday, July 29th. This represents a $0.88 dividend on an annualized basis and a yield of 0.2%. West Pharmaceutical Services's dividend payout ratio (DPR) is 11.27%.
Analysts Set New Price Targets
Several research firms have recently weighed in on WST. Zacks Research downgraded West Pharmaceutical Services from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 12th. Evercore reaffirmed an "outperform" rating and issued a $425.00 price target on shares of West Pharmaceutical Services in a research note on Monday, July 27th. TD Cowen reiterated a "buy" rating on shares of West Pharmaceutical Services in a report on Wednesday, July 15th. Stephens reiterated an "overweight" rating and set a $360.00 price objective on shares of West Pharmaceutical Services in a report on Tuesday, June 2nd. Finally, KeyCorp boosted their price objective on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the company an "overweight" rating in a research report on Thursday, July 2nd. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $368.08.
Check Out Our Latest Research Report on WST
West Pharmaceutical Services Profile
(
Free Report)
West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.
In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider West Pharmaceutical Services, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.
While West Pharmaceutical Services currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
